Counting the cost of public and philanthropic R&D funding: the case of olaparib

BACKGROUND: Lack of transparency around manufacturing costs, who bears the bulk of research and development costs and how total costs relate to the pricing of products, continue to fuel debates. This paper considers the case of olaparib (Lynparza®), recently indicated for use among BRCA-mutant breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, L., Sehic, O., Wild, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379234/
https://www.ncbi.nlm.nih.gov/pubmed/35974344
http://dx.doi.org/10.1186/s40545-022-00445-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379234/
https://www.ncbi.nlm.nih.gov/pubmed/35974344
http://dx.doi.org/10.1186/s40545-022-00445-9

Ejemplares similares